Idoxuridine

  • #LGM Pharma is a Idoxuridine CAS# 54-42-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 54-42-2
  • AHFC code: 52:04.20 84:04.06
  • Synonyms: 5-Iododeoxyuridine 5IDU 5IUDR Allergan 201 Allergan 211 ID2 Idossuridina [DCIT] Idoxuridin IDU IDUR Iododeoxyridine Iodoxuridine IUDR
  • ATC Code: D06BB01 J05AB02 S01AD01
  • Chemical Formula: C14H16N4
  • Molecular Weight: 354.0985
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00249 (APRD00504, DB03778, EXPT01835)
  • SMILES: OC[C,H]1O[C,H](C[C,,H]1O)N1C=C(I)C(=O)NC1=O
  • InChl: XQFRJNBWHJMXHO-RRKCRQDMSA-N
  • PubChem: 5905
  • IUPAC: 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione

Additional Details

Indication:
For use in keratoconjunctivitis and keratitis caused by herpes simplex virus.
Pharmacodynamics:
In chemical structure idoxuridine closely approximates the configuration of thymidine, one of the four building blocks of DNA (the genetic material of the Herpes virus). As a result, idoxuridine is able to replace thymidine in the enzymatic step of viral replication or "growth". The consequent production of faulty DNA results in a pseudostructure which cannot infect or destroy tissue. In short, by pre-empting a vital building block in the genetic material of the Herpes simplex virus, Herplex-D topical solution destroys the infective and destructive capacity of the viral material. The virus infected cell may only be attacked during the period of active synthesis of DNA. This occurs early in the development of the Herpes simplex lesion, but at different times in different cells. Therefore, ideally, the affected area should remain saturated with the antiviral agent.
Mode of Action:
Idoxuridine acts as an antiviral agent by inhibiting viral replication by substituting itself for thymidine in viral DNA. This in turn inhibits thymidylate phosphorylase and viral DNA polymerases from properly functioning. The effect of Idoxuridine results in the inability of the virus to reproduce or to infect/destroy tissue.
Metabolism:
Idoxuridine is rapidly inactivated by deaminases or nucleotidases.
Toxicity:
Hypersensitivity or increased sensitivity of eyes to light. LD50=3080 mg/kg (orally in mice).
General Reference:
Seth AK, Misra A, Umrigar D: Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. Pharm Dev Technol. 2004 Aug;9(3):277-89. Pubmed Otto SE: Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. Pubmed Fauth E, Zankl H: Comparison of spontaneous and idoxuridine-induced micronuclei by chromosome painting. Mutat Res. 1999 Apr 6;440(2):147-56. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos